The expression status of CD16 and SLAN was not determined in this study; however, they did show that the percentage of TIM-3 positivity on monocytes that also expressed CD206, a common marker for M2 macrophages, was significantly higher than on CD14+, CD206- monocytes from glioma patients suggesting that the M2 macrophage phenotype express higher TIM-3 and pro-tumor properties [70]. The gene discussed is SECISBP2L; the disease is glioma.